Astrazeneca/ Pacifica 4

NCT03833154 A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab following stereotactic body radiation therapy (SBRT) for the treatment of Patients with Stage I/II Non Small Cell Lung Cancer

Faculty Reference: 

An Institutional Review Board responsible for human subjects research at The University of Arizona reviewed this research project and found it to be acceptable, according to applicable state and federal regulations and University policies designed to protect the rights and welfare of participants in research.